Study of Otamixaban Versus Unfractionated Heparin (UFH) and Eptifibatide in Non-ST Elevation Acute Coronary Syndrome (SEPIA-ACS1)
This study has been completed.
Information provided by (Responsible Party):
First received: April 21, 2006
Last updated: November 17, 2014
Last verified: November 2014
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||March 2009|
|Primary Completion Date:||October 2008 (Final data collection date for primary outcome measure)|
|Certification or Request for Extension to Delay Results Received:||August 24, 2010|
Sabatine MS, Antman EM, Widimsky P, Ebrahim IO, Kiss RG, Saaiman A, Polasek R, Contant CF, McCabe CH, Braunwald E. Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial. Lancet. 2009 Sep 5;374(9692):787-95. doi: 10.1016/S0140-6736(09)61454-9. Erratum in: Lancet. 2009 Oct 31;374(9700):1502.